BenzingaDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:23:09·⟳ 抓取 19:23:18 +9s·⚡ 决策 10-19 19:24:19 +1m01s·8.3 天前
Benzinga财报前瞻：雅培(ABT)将于10月21日盘前公布Q3，分析师目标价120-135美元，无新增预期外信息
Benzinga财报前瞻稿汇总的一致预期(EPS1.41/营收129.9亿)是市场已定价的共识,所列5条评级动作最新为10/16、FDA批准为10/5,均非本文新增;没有任何预期差、指引变更或新订单/获批事实,财报本身要两天后才公布,不构成可交易的方向性催化。
📄 原文Benzinga↗ 原文
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings
Abbott Laboratories (NYSE:ABT) will release its third quarter earnings report before the opening bell on Wednesday, Oct…
不做 Abbott Laboratories(雅培)（ABT.US）
财报前瞻稿,无新增事实/预期差;共识与评级均为旧信息且已price-in,财报10/21才公布,此刻开仓等同赌方向,不做;待财报实际数据出来再作为独立事件研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是雅培Q3财报(10/21盘前)前的分析师评级与共识前瞻,全部为已知信息,无预期差也无新指引;在财报落地前做多做空均属赌方向,不做。
🔎 新鲜度:最早出现 2026-10-19 · 扩散 high · price-in 风险 high ↗
主要风险
- 10/21盘前实际财报若大幅超/低于共识或指引变动,会产生独立新催化,但属于另一事件,本前瞻稿无法预判
反向证据
- 做多前查反向 · 来源 web · 影响 none
本文未提供任何新利好或新利空;在财报落地前无法证伪/证实方向,反向与正向证据同样缺失,结论是无edge而非单边看多
检索:Abbott ABT Q3 2026 guidance warning cut recall lawsuit October
先例如何影响了这次决策
对本次决策的影响:确认不应以前瞻稿开仓;未给任何交易腿
方向:无可对照先例;本文非事件型催化而是财报前瞻,无需用先例校准
涨幅量级:无高相似对齐先例,且事件本身无增量,不据此定tp/sl
形态:财报前分析师前瞻稿通常不驱动方向性重定价,真正波动来自10/21财报本身
原文全文
展开原文 · 1,980 字
Abbott Laboratories (NYSE:ABT) will release its third quarter earnings report before the opening bell on Wednesday, Oct. 21.
Analysts expect the Abbott Park, Illinois-based company to report quarterly earnings of $1.41 per share, up from $1.30 per share in the year-ago period. The consensus estimate for ABT’s quarterly revenue is $12.99 billion. It reported $11.37 billion last year, according to Benzinga Pro.
On Oct. 5, Abbott received FDA approval for CardioMEMS HF System updates that add new patient-facing features through the CardioGuide HF App.
Shares of Abbott rose 0.2% to close at $104.89 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- TD Cowen analyst Joshua Jennings maintained a Buy rating with a price target of $135 on Oct. 16, 2026. This analyst has an accuracy rate of 57%.
- Barclays analyst Matt Miksic initiated coverage on the stock with an Overweight rating with a price target of $120 on Oct. 7, 2026. This analyst has an accuracy rate of 64%.
- Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $112 to $125 on Aug. 14, 2026. This analyst has an accuracy rate of 70%.
- Wolfe Research analyst Mike Polark upgraded the stock from Peer Perform to Outperform with a price target of $130 on Aug. 13, 2026. This analyst has an accuracy rate of 51%.
- Piper Sandler analyst Adam Maeder maintained an Overweight rating and increased the price target from $115 to $118 on July 17, 2026. This analyst has an accuracy rate of 56%.
Considering buying ABT stock? Here’s what analysts think:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
Analysts expect the Abbott Park, Illinois-based company to report quarterly earnings of $1.41 per share, up from $1.30 per share in the year-ago period. The consensus estimate for ABT’s quarterly revenue is $12.99 billion. It reported $11.37 billion last year, according to Benzinga Pro.
On Oct. 5, Abbott received FDA approval for CardioMEMS HF System updates that add new patient-facing features through the CardioGuide HF App.
Shares of Abbott rose 0.2% to close at $104.89 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- TD Cowen analyst Joshua Jennings maintained a Buy rating with a price target of $135 on Oct. 16, 2026. This analyst has an accuracy rate of 57%.
- Barclays analyst Matt Miksic initiated coverage on the stock with an Overweight rating with a price target of $120 on Oct. 7, 2026. This analyst has an accuracy rate of 64%.
- Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $112 to $125 on Aug. 14, 2026. This analyst has an accuracy rate of 70%.
- Wolfe Research analyst Mike Polark upgraded the stock from Peer Perform to Outperform with a price target of $130 on Aug. 13, 2026. This analyst has an accuracy rate of 51%.
- Piper Sandler analyst Adam Maeder maintained an Overweight rating and increased the price target from $115 to $118 on July 17, 2026. This analyst has an accuracy rate of 56%.
Considering buying ABT stock? Here’s what analysts think:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
04c5a29ae8· 2026-10-19 19:24 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前